What are the main indications for Upatinib/Refu?

Upadacitinib (Upadacitinib) is a broad-spectrum immunomodulatory targeted drug that is a Janus kinase (JAK) inhibitor that inhibits inflammatory responses by blocking the JAK-STAT signaling pathway. Different from traditional biological agents, it directly acts on the intracellular signal transduction link to inhibit the activity of inflammatory factors from the source, thereby achieving the purpose of controlling symptoms and delaying the progression of the disease.

Upadatinib tablets are mainly used to treat adults with moderate to severe rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), non-radiographic axial spondyloarthritis (nr-axSpA), ulcerative colitis (UC), Crohn's disease (CD) and giant cell arteritis (GCA). For such patients, upadatinib can significantly reduce pain, joint swelling and stiffness, and improve physical activity and quality of life. Especially in patients who are ineffective or intolerant to biologic agents such as tumor necrosis factor (TNF) blockers, upadatinib is often regarded as an ideal alternative. Clinical data shows that the drug can relieve joint inflammation in a short period of time, maintain long-term disease stability, and help reduce the recurrence rate of the disease.

In addition, an oral solution formulation of upadacitinib is approved for use in children 2 years and older with active polyarticular juvenile idiopathic arthritis (pJIA) and 2 to 18 years with active psoriatic arthritis (PsA). This expanded indication marks the extension of upadatinib from the treatment of adult diseases to the management of inflammation in children, providing a new oral treatment option for the long-term control of immune diseases in children.

It is important to note that although upadatinib has strong immunomodulatory ability, it is not recommended to be used in combination with otherJAK inhibitors, biologic DMARDs, or strong immunosuppressive drugs such as azathioprine and cyclosporine to avoid excessive suppression of the immune system and increased risk of infection. Doctors usually make individual treatment adjustments based on the patient's condition, previous medication history, and tolerance to ensure a balance between safety and efficacy.

Reference materials:https://www.rinvoq.com/